established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Liraglutide' with aliases Victoza, Saxenda, NN2211, Arg34-Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37) · 2026-09-27 04:00 · somebody
kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
fact added identity: CAS registry number 204656-20-2. · 2026-09-27 04:00 · somebody
fact added summary: Liraglutide is a glucagon-like peptide-1 analogue given by once-daily subcutaneous injection. · 2026-09-27 04:00 · somebody
fact added history: In the LEADER trial of 9,340 people with type 2 diabetes and high cardiovascular risk, fewer patients on liraglutide tha · 2026-09-27 04:00 · somebody
fact added history: A 56-week trial in 3,731 people with obesity and no diabetes studied the 3.0 mg daily dose alongside lifestyle counselli · 2026-09-27 04:00 · somebody